Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Corbus Pharmaceuticals will host a KOL event at ASCO 2026 to present updated Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC). The study includes 75 HNSCC participants and 317 total participants with advanced solid tumors, focusing on clinical response durability and subgroup analysis.
Key figures
- Drug Name
- CRB-701 (SYS6002)
- Phase Of Trial
- Phase 1/2
- HNSCC cohort size
- 75
- Total study participants
- 317
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.